Malignant osteopetrosis: c-src kinase is not reduced in fibroblasts

Related Experiment Video

Updated: Oct 20, 2026

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

G Meyerson1, N Dahl, S Påhlman

  • 1Department of Pathology, University Hospital, Uppsala, Sweden.

Calcified Tissue International
|July 1, 1993
PubMed

Insights

Disrupting the c-src gene causes osteopetrosis in mice. However, human osteopetrosis patients show normal c-src protein and kinase activity, suggesting c-src is not the cause in these cases.

Area of Science:

  • Genetics
  • Cell Biology
  • Molecular Biology

Background:

  • Osteopetrosis is a rare genetic bone disease characterized by impaired osteoclast function.
  • Targeted disruption of the c-src gene in mice results in a severe osteopetrosis phenotype.
  • The c-src gene is widely expressed, making it a potential candidate for involvement in human osteopetrosis.

Purpose of the Study:

  • To investigate the role of c-src gene expression in human malignant, congenital osteopetrosis.
  • To determine if alterations in c-src protein levels or kinase activity are associated with human osteopetrosis.

Main Methods:

  • Fibroblast cell cultures were established from three individuals diagnosed with malignant, congenital osteopetrosis.
  • Fibroblasts from healthy individuals served as controls.
  • Western blot analysis and kinase assays were performed to quantify c-src protein levels and kinase activity.

Main Results:

  • No significant differences were observed in c-src protein expression levels between osteopetrosis patients and healthy controls.
  • c-src kinase activity was comparable in fibroblasts from both affected individuals and controls.
  • These findings indicate normal c-src function in the studied human osteopetrosis cases.

Conclusions:

  • Impairment of c-src gene function is unlikely to be the primary etiological factor in the investigated cases of human malignant, congenital osteopetrosis.
  • Further research is needed to identify the genetic basis of osteopetrosis in these individuals.
  • This study highlights the importance of investigating specific gene functions in the context of human genetic diseases.

More Related Videos

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation09:37

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation

Published on: March 15, 2018

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...